Page 5 - Nasdaq Repl News Today

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) fell 3.8% during trading on Wednesday . The company traded as low as $19.24 and last traded at $19.24. 16,801 shares changed hands during trading, a decline of 97% from the average session volume of 567,215 shares. The stock had previously closed at $20.00. Analyst Upgrades and Downgrades […]

WOBURN, Mass., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development...

BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a...

A number of firms have modified their ratings and price targets on shares of Replimune Group (NASDAQ: REPL) recently: 5/25/2022 – Replimune Group was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes […]

Replimune Group, Inc. (NASDAQ:REPL – Get Rating) – Analysts at Wedbush issued their FY2024 earnings per share estimates for shares of Replimune Group in a research note issued to investors on Tuesday, May 24th. Wedbush analyst R. Driscoll anticipates that the company will earn ($2.77) per share for the year. Wedbush currently has a “Outperform” […]

Replimune Group (NASDAQ:REPL – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of […]

Replimune Group (NASDAQ:REPL – Get Rating) had its price target reduced by Piper Sandler from $52.00 to $44.00 in a report issued on Thursday, The Fly reports. Piper Sandler’s price objective would suggest a potential upside of 201.16% from the stock’s previous close. A number of other brokerages have also recently commented on REPL. BMO […]

Replimune Group (NASDAQ:REPL – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research note issued on Wednesday, Zacks.com reports. According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s […]

Replimune Group (NASDAQ:REPL – Get Rating) had its price target dropped by equities researchers at JPMorgan Chase & Co. from $47.00 to $39.00 in a note issued to investors on Monday, Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price target suggests a potential upside of 98.27% […]

Shares of Replimune Group, Inc. (NASDAQ:REPL – Get Rating) have earned a consensus recommendation of “Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target […]